Stockwinners Market Radar for May 29, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:43 EDT Teva says FDA approves AUSTEDO XR as one pill, once-daily - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths indicated in adults for TD and HD chorea. "Since our launch of AUSTEDO in 2017, we have been committed to helping people living with TD and HD chorea treat these chronic, involuntary movements," said Dell Faulkingham, Senior Vice President, Head of U.S. Innovative Medicines at Teva. "AUSTEDO, backed by the longest efficacy and tolerability data to date, has continued to evolve - having received approval for AUSTEDO XR, our once-daily extended-release formulation in February 2023. This latest milestone offers a streamlined treatment regimen for clinically therapeutic doses with the broadest dosing flexibility."

18:35 EDT Chipotle CEO: Consumers are becoming more thoughtful about eating out - In an interview on CNBC's Mad Money, Brian Niccol said the company has never shrunk its portion sizes. "We always said we want to give people great portions." As a company we're focused on throughput, he noted. Niccol "definitely sees" a path to 7,000 restaurants, and thinks that goal will be surpassed.

17:59 EDT First Guaranty Bancshares CEO Alton Lewis retiring, Michael Mineer succeeds - First Guaranty Bancshares announced that Alton Lewis will retire from his role as President and CEO of First Guaranty Bancshares and First Guaranty Bank in May. Lewis began his service as Board member in 1988 and became President and CEO in 2009. Lewis will continue to serve as Vice Chairman of the Holding Company and Bank Board of Directors. Michael Mineer will become the First Guaranty Bancshares and First Guaranty Bank next President and CEO. Mineer is the Mideast Area President.

17:41 EDT Treace Medical director buys $253.5K in common stock - In a regulatory filing, Treace Medical disclosed that its director James Treace bought 50K shares of common stock on May 28th in a total transaction size of $253.5K.

17:33 EDT Salesforce says seeing measured buying behavior which impacted Q1 - Says currently managing 250 petabytes of customer data. Sees FY25 subscription revenue up slightly below 10%. Sees FY25 operating margin 32.5%. Says added more than 1,000 data cloud customers. Says incredibly well positioned for AI transformation. Says momentum in Q4 moderated in Q1. Says seeing impressive growth in data cloud. Says seeing momentum in Einstein AI. Says seeing measured buying behavior. Says anticipating quarterly dividend next month. Sees FY25 capital expenditures slightly below 2% of revenue. Comments and guidance taken from Q1 earnings conference call.

17:20 EDT Palantir awarded $480M Army contract for Maven Smart System prototype - Palantir was awarded a $480M firm-fixed-price contract for the Maven Smart System prototype. One bid was solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of May 28, 2029. U.S. Army Contracting Command is the contracting activity.

17:17 EDT Leidos awarded $738.45M Air Force contract - Leidos was awarded a $738.45M indefinite-delivery/indefinite-quantity contract for Air Force National Capital Region, or NCR, information technology services. This contract provides for a full range of classified and unclassified information technology and telecommunication services in the National Capital Region. This contract also provides services to the National Military Command Center's strategic watch, crisis response, and worldwide monitoring missions. Work is expected to be completed by September 2, 2029. This contract was a competitive acquisition, and one offer was received. The Air Force District of Washington NCR Enterprise Support Division is the contracting activity.

17:09 EDT Zimmer Biomet board approves new stock buyback authorization for up to $2B

16:54 EDT VNET Group sees FY24 revenue RMB 7.8B-8.0B, up 5.2%-7.9% from last year

16:38 EDT Planet Fitness announces proposed refinancing transaction - Planet Fitness announced that certain of its subsidiaries intend to complete a refinancing transaction, which will include the issuance of a new series of securitized debt under their existing securitized financing facility and repayment of their existing Series 2018-1 Class A-2-II Notes. The company had approximately $2B of outstanding debt under its existing securitized financing facility as of March 31, 2024. The company intends to issue $600M in Series 2024-1 Fixed Rate Senior Secured Notes, Class A-2, with the potential to upsize up to $800M, subject to market conditions and other factors. The net proceeds of the securitized financing facility are expected to be used: to repay in full the Series 2018-1 Class A-2-II Notes, which as of March 31, 2024, had a principal balance of approximately $591M; to pay the transaction costs and fund the reserve accounts associated with the securitized financing facility; and for general corporate purposes, which may include funding share repurchases by the company.

16:33 EDT Castle Biosciences publishes study on DecisionDx in SCC patients - The company "announced the publication of a study in the International Journal of Radiation Oncology * Biology * Physics demonstrating the ability of the DecisionDx-SCC test to identify high-risk cutaneous squamous cell carcinoma, or SCC, patients at the highest risk of metastasis who will benefit the most from ART to reduce metastatic disease progression, as well as high-risk patients who the test identified as having a lower risk of metastasis who may consider deferring treatment. These results demonstrate the impact of the test in guiding decision-making for recommending ART. The DecisionDx-SCC test identified patients projected to receive the greatest benefit from ART to reduce metastatic disease progression. Patients with a Class 2B (highest metastatic risk) test result who were treated with ART had 50% higher MFS rates, on average, than Class 2B patients who did not receive ART at five years post-diagnosis. Class 2B patients who received ART showed a significant deceleration in disease progression compared to Class 2B patients who did not receive ART. For patients with a DecisionDx-SCC Class 2B test result who were not treated with ART, there was a peak rate of metastasis around two years; Class 2B, ART-treated patients had nearly five times longer projected time to metastasis."

16:26 EDT FutureFuel CEO Tom McKinlay to retire - FutureFuel announced that Tom McKinlay, FutureFuel's CEO, informed FutureFuel that he will retire effective September 30. FutureFuel has retained an executive search firm to conduct a nationwide search to replace McKinlay as CEO. FutureFuel and McKinlay have entered into a separation agreement to provide for an orderly transition of McKinlay's duties and responsibilities

16:22 EDT Trxade Health gets Nasdaq late filing notice for quarterly report on 10-Q - Trxade Health announced that, on May 23, the Company received a notice rom the Nasdaq Listing Qualifications Department indicating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the period ending March 31 the Company is not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250 c1 Listing Rule , which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission The Notice indicates that the Company must, no later than July 22 submit a plan to regain compliance with respect to the filing requirement. Following receipt of such plan, Nasdaq may grant an extension of up to 180 calendar days from the Form 10-Q due date, or until November 18, 2024, for the Company to regain compliance.

16:21 EDT Virgin Galactic receives NYSE continued listing standard notice - Virgin Galactic Holdings announced that on May 29, 2024 it received a notice from the New York Stock Exchange that the average closing price per share of its common stock did not exceed $1.00 over a 30 consecutive trading-day period, which is required for continued listing on the NYSE. The company has notified the NYSE of its intent to regain compliance with the continued listing standards by seeking stockholder approval at its upcoming annual meeting of stockholders on June 12, 2024 to complete a reverse stock split of the company's common stock. Virgin Galactic filed a proxy statement with the U.S. Securities and Exchange Commission on April 29, 2024 that contains additional details about the proposed reverse stock split.

16:18 EDT Tutor Perini JV awarded $74.4M contract by NFESC - Tutor Perini Corporation announced that its subsidiary, Black Construction Corporation, in a joint venture with the Company, has been awarded a contract valued at approximately $74.4 million by the U.S. Naval Facilities Engineering Systems Command, Pacific District for a Child Development Center at Andersen Air Force Base, Guam. The scope of work includes construction of a Child Development Center facility with privately owned vehicle parking. The facility will feature a single-story, reinforced concrete building consisting of child development spaces, core administration, staff support, facility support spaces, outdoor storage and activity spaces and incidental related work. Construction will also include shallow, reinforced concrete foundations, slabs, walls, floors and roof, fluid applied roofing, doors, windows, louvers, exterior and interior finishes, kitchen equipment, signage, plumbing, ventilation, electrical power, lighting and telecommunications. Sitework will include grading, landscaping, walkways, fencing, equipment and trash enclosures, sewer, water, electrical and telecommunication utilities and environmental mitigation consisting of cultural and natural resources, and munitions, explosives of concern and incidental related work. Work is expected to begin this summer with substantial completion anticipated in the summer of 2026. The contract value will be included in the Company's backlog beginning in the second quarter of 2024.

16:15 EDT Nutanix down 8% at $67.45 after Q3 results and narrowed guidance

16:14 EDT C3.ai jumps 13% to $27.00 after Q4 results and guidance

16:11 EDT UiPath to re-appoint Daniel Dines as CEO - UiPath announced Rob Enslin is resigning as Chief Executive Officer and member of the UiPath Board of Directors effective June 1, 2024. Daniel Dines, founder and former CEO of UiPath, will be re-appointed CEO, also effective June 1, 2024. Dines currently serves as Chief Innovation Officer and Executive Chairman of the Board. Enslin will stay engaged with UiPath as an advisor during the transition. Dines co-founded UiPath in 2005 and served as CEO or co-CEO and Executive Chairman from that time through Jan. 31, 2024, when he assumed the role of Chief Innovation Officer and Executive Chairman. Enslin joined UiPath as co-CEO of the company in April 2022 and served as sole CEO from Feb. 1, 2024 until present.

16:10 EDT Post Holdings reports avian influenza at 3rd-party egg-laying facility - Post Holdings, provided information regarding avian influenza incidents at two of Michael Foods' third-party contracted egg-laying facilities. Post also affirmed its non-GAAP Adjusted EBITDA guidance for fiscal year 2024. Michael Foods' third-party contracted egg-laying flocks in Minnesota and Iowa tested positive for avian influenza. The facilities house approximately 5.7M egg-laying hens, or approximately 14% of Post's controlled supply, inclusive of owned and third-party contracted farms.

16:09 EDT Red Robin: Comparable restaurant revenue in first five weeks of Q2 up 0.3% - Comparable restaurant revenue in the first five weeks of the second quarter of fiscal 2024 increased 0.3% as compared to the same weeks in 2023.

15:53 EDT Air Products to build network of multi-modal hydrogen refueling stations in CA - Air Products announced it intends to build a network of permanent, commercial-scale, multi-modal hydrogen refueling stations stretching from Northern California to Southern California. Eric Guter, Air Products' Vice President, Hydrogen for Mobility, made the announcement during his keynote address at the California Hydrogen Convention at the Los Angeles Convention Center. The permanent, multi-modal hydrogen refueling stations will be equipped to serve heavy-duty vehicles, such as commercial and municipal trucks and buses, as well light-duty hydrogen fuel cell vehicles. "Each state-of-the-art, high-capacity, high-reliability station will be able to fuel up to 200 heavy-duty trucks or 2,000 cars per day," said Alison Hawkins, Air Products' General Manager - Hydrogen for Mobility, Americas. "These stations will be a key driver to help California on its road to a zero-emissions transportation future."

14:52 EDT NextCure treatment of osteogenesis imperfecta granted orphan designation - NextCure's treatment of osteogenesis imperfecta was granted orphan designation by the FDA, according to a post to the agency's website. Reference Link

14:39 EDT Goldman veteran Beth Hammack named next Cleveland Fed president - The Federal Reserve Bank of Cleveland said, in part, earlier on Wednesday: The Federal Reserve Bank of Cleveland announced the appointment of Beth M. Hammack as its next president and chief executive officer. In this role, Hammack will represent the Fourth Federal Reserve District on the Federal Open Market Committee in the formulation of US monetary policy and will lead the 1,100 employees of the Cleveland Fed...."Beth has a deep understanding of financial markets and the monetary policy transmission process, expertise in leading complex business lines, and a proven commitment to mission-focused work. Her appreciation for the diversity, history, and natural beauty of the Fourth District stood out during the interview process, as did her enthusiasm to make the region her home. The search committee is confident that Beth will employ all these qualities, along with her strategic mindset and talent for clear, accessible communication, in her new role serving the public," Gartland continued. Hammack has more than 30 years of experience in finance, capital markets, and risk management, as well as service on several advisory groups to the US Department of the Treasury and the financial industry. Most recently, she was cohead of global financing at the Goldman Sachs Group, where she was a member of the management committee. Her previous roles at the firm include global treasurer, global head of short-term macro trading, and global head of repo trading. Reference Link

14:34 EDT AERWINS Technologies Inc trading resumes

14:29 EDT AERWINS Technologies Inc trading halted, volatility trading pause

14:00 EDT CAE's SkyAlyne JV awarded C$11.2B contract for Canada's FAcT Program - CAE announced that its SkyAlyne joint venture was t awarded a C$11.2B, 25-year contract for Canada's Future Aircrew Training Program. "CAE has proudly worked alongside the Royal Canadian Air Force (RCAF) for more than 75 years to design and deliver training, services, and technologies that support the mission readiness of Canada's aviators," said Marc Parent, CAE's President and Chief Executive Officer. "Today's announcement regarding the Future Aircrew Training Program is a significant achievement in the ongoing modernization efforts of Canada's defence forces. FAcT is a transformational win for SkyAlyne and CAE, laying the groundwork for training technologies and processes enabling mission readiness. As an industry leader in civil and defence simulation training and critical operations, CAE is proud to be part of the future of aircrew training to Canada."

13:31 EDT Greenwave Technology announces reverse stock split to regain Nasdaq compliance - Greenwave Technology Solutions announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share at a ratio of 1 post-reverse split share for every 150 pre-reverse split shares. The reverse stock split will become effective at 5:00 p.m. Eastern Standard Time on Friday, May 31, 2024. The Common Stock will continue to be traded on The Nasdaq Capital Market under the symbol GWAV and will begin trading on a reverse split-adjusted basis when the market opens on Monday, June 3, 2024. The reverse stock split is intended to increase the per-share trading price of the Common Stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

12:53 EDT Nissan issues 'Do Not Drive' warning for nearly 84,000 vehicles, says NHTSA - According to NHTSA, Nissan has issued a "Do Not Drive" warning today for 83,920 model year 2002-2006 vehicles equipped with recalled, unrepaired Takata air bags. "If you have one of these vehicles, do not drive it until the repair is completed and the defective air bag is replaced," NHTSA said. The warning covers certain model year 2002-2006 Nissan Sentra, 2002-2004 Nissan Pathfinder and 2002-2003 Infiniti QX4 vehicles that are subject to open Takata air bag recalls under NHTSA recall campaigns 20V-008 and 20V-747. NHTSA is urging all vehicle owners to immediately check to see if their vehicle has an open Takata air bag recall. If it does, owners should contact their dealership to schedule a free repair as soon as possible and follow any warnings from the vehicle manufacturer. Nissan and Infiniti are offering free towing, mobile repair, and in select locations, loaner vehicles. Reference Link

12:50 EDT NHS England to wait to see final results before rollout of Galleri test - NHS England offered the following update on the ongoing NHS-Galleri trial: "Based on data from the first year of the three-year NHS-Galleri trial, NHS England has decided that it will wait to see final results, expected in 2026, before considering whether an NHS rollout of the Galleri multi cancer early detection test - the Multi Cancer Blood Test Programme, MCBT -should go ahead. NHS England's commercial agreement with health technology company GRAIL in November 2020 positioned the NHS at the forefront of an exciting area of healthcare innovation, and the company's Galleri test is now being subjected to one of the most rigorous investigations in any healthcare system worldwide. Over 140,000 people between the ages of 50 and 77 years have taken part in what is the world's largest prospective trial of a multi cancer early detection blood test." Reference Link

12:14 EDT FDA grants Lilly's Retevmo accelerated approval for thyroid cancer - The Food and Drug Administration said it granted accelerated approval to Eli Lilly's selpercatinib, named Retevmo, for pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation, advanced or metastatic thyroid cancer with a RET gene fusion, and locally advanced or metastatic solid tumors with a RET gene fusion. This is the first FDA approval of a targeted therapy for pediatric patients less than 12 years of age with RET alterations. Selpercatinib was previously granted accelerated approval for the thyroid cancer indications in adults and pediatric patients 12 years of age and older.

12:04 EDT Abercrombie & Fitch rises 18.7% - Abercrombie & Fitch is up 18.7%, or $28.48 to $180.87.

12:02 EDT Nordic American Tankers falls -8.4% - Nordic American Tankers is down -8.4%, or -35c to $3.88.

12:00 EDT Biohaven falls -18.4% - Biohaven is down -18.4%, or -$6.98 to $30.96.

11:37 EDT U.S. video game spending fell 3% y/y in April, says Circana - Circana analyst Mat Piscatella said that projected total U.S. spending on video game hardware, content and accessories fell 3% in April 2024 vs YA, to $4.1B. A 2% increase in content spending could not offset a 43% drop in hardware and a 4% dip in accessories. The content spending growth was led by mobile, with gains from this segment offsetting a 24% year-on-year dip in content spending on Console platforms. April video game hardware spending fell 43% when compared to a year ago, to $208M. All current console hardware platforms fell a minimum of 26% year-on-year, with Switch (NTDOY) showing the strongest year-on-year decline at 69%. PlayStation 5 (SONY) again led the month's hardware market in unit and dollar sales. Nintendo Switch once again finished 2nd in unit sales, while Xbox Series (MSFT) ranked 2nd in dollars. PS5 exclusive "Stellar Blade" debuted as the best-selling premium game of April, and the #16 best-selling game of 2024 year-to-date. "Stellar Blade" was the only new release in April to rank among the month's top 20 best-selling premium video games. Sony's "Helldivers II" remains the best-selling premium game of 2024 year-to-date after placing 2nd in April, repeating its March ranking. "Helldivers II" held to its #2 ranking despite April dollar sales falling by more than 70% when compared to March. Microsoft's "Sea of Thieves," which originally launched on Xbox and PC in 2018, was the 4th best-selling game of April following its launch on PlayStation platforms during the month. The title ranked 55th on the March best-selling titles chart. "Sea of Thieves" was the #3 best-selling game on PlayStation platforms in April. Other top-selling premium games in the U.Sgreater than for the month were Activision's "Call of Duty: Modern Warfare III," Bethesda's "Fallout 4," Sony's "MLB The Show 24," Capcom's (CCOEY) "Dragon's Dogma II," Warner Bros. Disccovery's (WBD) "Hogwarts Legacy," and Electronic Arts' (EA) "EA Sports FC 24." Reference Link

11:14 EDT U-BX Technology Ltd trading resumes

11:04 EDT Lithium Ionic announces feasibility study results for Bandeira Lithium Project - Lithium Ionic announced the results of a Feasibility Study for its 100%-owned Bandeira Lithium Project located in Minas Gerais, Brazil. The Bandeira claims span 157 hectares, which represents only about 1% of Lithium Ionic's extensive 14,182-hectare land package in Brazil's 'Lithium Valley', a region of global significance for hard-rock lithium production. Highlights of the Feasibility Study for the Bandeira Project: Mine Life & Production: 14-year underground mining operation producing an average of 178,000t of high-quality spodumene concentrate grading 5.5% Li2O. Strong Project Economics: After-tax net present value of US$1.3 billion and after-tax internal rate of return of 40% at average SC5.5 price of $2,277/t. Industry-leading Operating Costs: All-in LOM OPEX of $444/t of SC5.5 Low Capital Intensity: Total capital expenditure of US$266 million with after-tax payback of 3.4 years. LOM sustaining costs of US$ 81 million. Minimal Land-use Footprint: The development plan contemplates an underground mining operation with a simple processing circuit to optimize recoveries while minimizing the impact on the environment and local communities. Responsible Tailings Management: For safety and environmental reasons, the mine will utilize dry stacking waste disposal, which among other benefits will reduce water usage and facilitating site rehabilitation. Local Social & Economic Contributions: Total estimated taxes payable of $915 million, a peak local workforce of ~870 direct employees, and an estimated $677 million procuring goods and services within Brazil over the life of mine. Construction Permits on Track for mid-2024: The LAC license application submitted in November is currently under review by the state agency. Approval is expected in early Q3 2024.

10:04 EDT Advance Auto Parts falls -9.3% - Advance Auto Parts is down -9.3%, or -$6.53 to $63.65.

10:03 EDT Biohaven falls -27.3% - Biohaven is down -27.3%, or -$10.37 to $27.57.

10:02 EDT IBM, ID Dataweb expand relationship for identity verification - ID Dataweb announced an expanded relationship with IBM to integrate ID Dataweb's identity verification workflows within IBM Security Verify. By combining the two solutions, organizations will be able to confirm the identity of a user within existing workflows as their credentials are being seamlessly issued and used.

10:01 EDT Chewy rises 21.0% - Chewy is up 21.0%, or $3.55 to $20.46.

09:52 EDT Southwest falls -6.8% - Southwest is down -6.8%, or -$1.80 to $24.71.

09:50 EDT Biohaven falls -25.7% - Biohaven is down -25.7%, or -$9.74 to $28.20.

09:48 EDT Toast sees mid-term adjusted EBITDA 30%-35% of total business - Sees achieving adjusted EBITDA margin target in 2-3 years. Raises long-term target margins to 40%+. Comments taken from Investor Day presentation slides.

09:47 EDT Ooma rises 17.0% - Ooma is up 17.0%, or $1.34 to $9.24.

09:44 EDT Catalyst Biosciences Inc trading resumes

09:41 EDT Life Time Group partners with Olympian Ryan Lochte to offer swim clinics - Life Time is teaming up with world-renowned swimmer, current World Record Holder, and 12-time Olympic Medalist, Ryan Lochte, to offer a series of swim clinics across several of its athletic country clubs. These exclusive clinics, available for all ages, will provide a unique opportunity to learn from one of the greatest swimmers in history in partnership with Life Time's leading aquatics experts. The 3-hour clinics include in-water instruction with drills, starts and turns, plus a Q&A session, tips on nutrition, post-race recovery, injury prevention, motivation and overcoming obstacles. All swimmers in attendance will receive an autographed swim cap and picture with Ryan

09:39 EDT Visionary Holdings Inc trading resumes

09:34 EDT Catalyst Biosciences Inc trading halted, volatility trading pause

09:33 EDT Nevada reports April statewide gaming win up 6.95% to $1.24B - Nevada reports April Las Vegas Strip gaming win up 6.62% to $666.06M versus last year. Publicly traded companies in the gambling space include include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (FLUT), Gan Limited (GAN), Genius Sports (GENI), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), Rush Street Interactive (RSI), Sportradar (SRAD) and Wynn Resorts (WYNN).

09:30 EDT Mullen Automotive announces commercial EV fleet order for Europe - Mullen Automotive announces a new European purchase order for 40 Mullen-GO urban delivery vehicles with Switzerland-based Antidoto SA, a commercial upfitter whose key focus is on-demand food delivery companies. The initial PO is valued at $440,000. Antidoto SA specializes in the design and sale of pizza ovens for delivery vehicles and installs warming ovens in various types of vehicles. The company currently produces around 500 ovens per year, which are integrated and sold with a specific vehicle. Antidoto SA will initially order 40 Mullen-GO vehicles for 2024 and projects a minimum order of 180 units for 2025 to meet anticipated growing demand for zero emission EVs. The vehicles will initially be deployed in Switzerland with planned expansion into other parts of Europe.

09:28 EDT Petros Pharmaceuticals completes human factors study of AI-integrated web app - Petros Pharmaceuticals announces the completion of a Formative Human Factors study of its AI-integrated Web App, designed to facilitate OTC access of STENDRA for consumers. This important development follows the Company's recent execution of an AI licensing agreement with a leading multi-billion dollar software provider announced earlier this year. The Web App is an integral part of the Company's efforts to complete an Rx-to-OTC switch for STENDRA under the guidance of the U.S. Food and Drug Administration. The study demonstrated a 90% or better error-free completion rate for nearly all 5,820 tasks assessed. The successful completion of the study paves the way for the Company to initiate the next stage of the evolving program, while continuing to optimize the AI component of the Web App. The Formative Human Factors study was conducted in a population of 30 consumers, including a cohort with limited literacy. The consumers were provided with five different use scenarios requiring correct demonstration of 194 different tasks using the Web App with no training or guidance. The study also included a proprietary AI interface that confirmed the identity of the consumer, a first-ever innovation for an Rx-to-OTC switch program.

09:24 EDT Catalent stockholders approve transaction with Novo Holdings - Catalen announced that, at its Special Meeting of Stockholders held earlier, its stockholders voted to approve the pending transaction under which Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash . "Today's outcome represents an important milestone towards the closing of this transaction, and we thank our stockholders for their overwhelming support and their confidence in the future of Catalent," said Alessandro Maselli, President and Chief Executive Officer of Catalent. "Following the closing of the transaction, we look forward to writing the next chapter for Catalent, benefiting from Novo Holdings' expertise and resources as we continue to be a global leading independent CDMO, developing, manufacturing and supplying products that help people live better and healthier lives." Based on the preliminary count of the voting results from today's Special Meeting, Catalent stockholders voted to approve the transaction with 99.2% of ballots cast in favor of the proposed transaction. Catalent anticipates filing the final voting results for its Special Meeting in a Form 8-K with the Securities and Exchange Commission, after certification by Catalent's inspector of elections. The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. The transaction is not subject to any financing contingency.

09:16 EDT Transcode Therapeutics reports data from FIH study of TTX-MC138 - TransCode Therapeutics announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity. New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate's molecular target, miRNA-10b, in the patient's blood. Specifically, after injection, the amount of miR-10b in the patient's blood was significantly reduced compared to levels prior to administration of radiolabeled TTX-MC138, reaching a reduction of 66% at 24 hours following dosing. "We believe these data are important given that in several animal models, miRNA-10b inhibition by TTX-MC138 resulted in complete regressions of metastatic disease," stated Zdravka Medarova, PhD, Chief Scientific Officer at TransCode. These data support TransCode's belief that clinical development of TTX-MC138 has the potential for clinical benefit in patients with metastatic cancer. In addition, the study also quantified the amount of drug candidate delivered to metastatic lesions, providing further evidence that TTX-MC138 accumulated in metastatic tumors. The increase of radioactive lesion-to-blood ratios suggests that circulating TTX-MC138 is actively taken up by the cancerous tissue. The microdose of radiolabeled TTX-MC138 was well tolerated with no adverse events observed. Full data analysis is ongoing and will be included in the final study report

09:13 EDT Arista in collaboration with Nvidia delivers holistic AI solutions - Arista Networks (ANET) announced a technology demonstration of AI Data Centers in order to align compute and network domains as a single managed AI entity, in collaboration with NVIDIA (NVDA). In order to build optimal generative AI networks with lower job completion times, customers can configure, manage, and monitor AI clusters uniformly across key building blocks including networks, NICs, and servers. This demonstrates the first step in achieving a multi-vendor, interoperable ecosystem that enables control and coordination between AI networking and AI compute infrastructure..."Arista aims to improve efficiency of communication between the discovered network and GPU topology to improve job completion times through coordinated orchestration, configuration, validation, and monitoring of NVIDIA accelerated compute, NVIDIA SuperNICs, and Arista network infrastructure," said John McCool, Chief Platform Officer for Arista Networks.

09:12 EDT Teradyne appoints Jame Davidson as Chief AI Officer - Teradyne Robotics has announced the appointment of James Davidson as the Chief Artificial Intelligence Officer effective May 28, 2024. Most recently, as Chief Architect at Mobile Industrial Robots, he guided its technical direction and ramped up AI solutions for its new product, the MiR1200 Pallet Jack.

09:10 EDT Sensormatic Solutions teams with Thruvision for 'people' security screening - Sensormatic Solutions, the global retail solutions portfolio of Johnson Controls announced its partnership with Thruvision, a global provider of walk-through security screening technology, which will enable next-generation people screening to become more accessible to retailers around the world. Using passive terahertz camera technology, Thruvision's cameras and scanning software complement Sensormatic Solutions robust loss prevention solutions portfolio and will provide retailers with a fast, respectful and reliable people-screening option in distribution centers and other logistics facilities to address and help reduce internal shrink. Thruvision's offering is available now through Sensormatic Solutions. "The discussion about retail theft often focuses on sales floors and through the organized retail crime, ORC lens, but internal theft is a growing problem..."

09:09 EDT Neo-Concept announces APA to acquire IP of affiliated company - Neo-Concept International announced a game-changing acquisition. The company has signed an Asset Purchase Agreement, APA, to acquire the intellectual property, IP, and R&D capabilities of its affiliated company, Neo-Concept Company Limited. Under the deal, NCI will take full ownership of the highly-valuable "Les100Ciels" and "SIU" brands, including all associated trademarks and trade names. Crucially, this includes the transfer of the R&D teams responsible for these in-demand labels. "This strategic move turbocharges our retail expansion, especially in the booming Middle East markets," declared Miss Eva Siu, Chairlady and CEO of NCI. "The current licensing model simply doesn't give us the control we need. Now, with full IP ownership, we can supercharge our growth plans."

09:08 EDT Cboe Global Markets plans to expand credit futures for trading on Cboe - Cboe Global Markets announced plans to list Cboe iBoxx $ Emerging Market Bond Index futures for trading on Cboe Futures Exchange beginning on June 17, subject to regulatory review. The IEMD futures will be based on the S&P Dow Jones Indices' iBoxx USD Liquid Emerging Market Sovereigns & Sub-Sovereigns Index. IEMD futures are designed to offer investors exposure to U.S. dollar denominated bonds issued by governments or sub-sovereign issuers from emerging market countries. For current and potential emerging market debt investors, IEMD futures could be used to hedge existing exposures, implement relative value strategies against other fixed income instruments and manage interest rate and credit risk. IEMD futures will be exchange-traded and centrally cleared, which will help provide operational simplicity and limit counterparty risk compared to over-the-counter instruments.

09:07 EDT Helius Medical announces third-party reimbursement for PoNS - Helius Medical Technologies announced the first third-party reimbursement from a major insurance carrier for the Company's Portable Neuromodulation Stimulator device. The reimbursed rate, net of a 7% rebate, results in pricing of $16,554 for the controller and $7,347 for the mouthpiece, exclusive of rounding.

09:06 EDT LPL Financial: FSI Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that the advisors of FSI Wealth Management have joined LPL Financial's broker-dealer, RIA and custodial platforms. The team reported serving approximately $215 million in advisory, brokerage and retirement plan assets and joins LPL from Securities America, now part of Osaic. FSI founding partners Paul Neves, CFP, ChFC, and Darrin Santos, CFP, have more than 65 years of combined experience in the financial services industry. They teamed up in 1995 to build a financial planning-based firm in Old Town, San Diego, where they are supported by two office associates. Their entrepreneurial spirit is evident in their comprehensive approach to wealth management, which includes working closely with CPAs, attorneys, insurance brokers and other consultants to consider all aspects of their clients' financial lives.

09:05 EDT Treasure Global secures $2M smart campus management system contract - Treasure Global announces that it has been awarded a contract estimated at $2M by ELMU Education Group Sdn Bhd, ELMU, for the deployment of a cutting-edge Smart Campus Management System. ELMU's Smart Campus Solution, set to be deployed by Treasure Global, represents a transformative approach to campus management. Designed to achieve comprehensive energy data insights and advanced device management, this innovative system leverages a unified IoT platform to enable rapid visualization of energy data. Supporting more than 2,200 categories of smart hardware devices and integrating over 500,000 smart hardware devices, the platform empowers educational institutions to expand their product offerings and swiftly capitalize on market opportunities.

09:04 EDT Fat Brands' Fazioli's opens second location in Tampa Area - Fazoli's, a quick-service chain owned by FAT Brands, has officially opened its second location in the Tampa area. "We're proud to open our sixth location in Florida, which underscores our commitment to expanding in the state," said Gregg Nettleton, President of Fazoli's. "We have incredible fans in Florida who continue to welcome us from day one. From waiting in opening day lines to ordering their fair share of unlimited breadsticks, their dedication to the brand makes each opening special. We expect the same success in Lutz with our fast, fresh, and affordable Italian cuisine."

09:03 EDT YY Group expands footprint into United Arab Emirates hotel industry - YY Group Holding announced its entry into the United Arab Emirates hotel and hospitality industry. Ramy Attia will serve as the Country Director. "This expansion will give YY Group the ability to serve multinational and regional hospitality brands, helping them effectively manage their operations in the UAE. With a proven record of providing qualified and experienced workers to leading hospitality companies in Southeast Asia, we expect to hit the ground running and quickly gain traction," said Mike Fu, Founder and Chief Executive Officer of YY Group. "Ramy brings more than 17 years of hospitality experience across five countries to the Company, and we look forward to working closely with him and his team to capitalize on the expected growth of the hotel and hospitality industries within the UAE."

09:02 EDT Ansys launches Access on Microsoft Azure - Ansys (ANSS) announced the launch of Ansys Access on Microsoft (MSFT) Azure to enable seamless deployment of pre-configured Ansys products on Azure cloud platform infrastructure. Available May 30, customers using their own Azure subscription with existing Ansys licenses can benefit from a more scalable, secure, and cost-effective approach to running HPC simulations in the cloud. As cloud computing continues to gain traction across industries, the demand for purpose-built hardware focused on HPC requirements has increased. Additionally, there are many challenges that need to be addressed when using simulation in the cloud. These include validating on-premises workloads that have been shifted to the cloud, the ongoing work to deploy and test new virtual machines and configuring adjacent cloud-based infrastructure in a cost-effective manner.

09:02 EDT Sintx Technologies signs agreement to enter Korean technical ceramics sector - SINTX Technologies announced that it has entered into a 5-year strategic agreement with Myosung. Myosung is one of several companies created and managed by their Founder and Chairman, Dr. Lee Boo Rak, from the Republic of Korea. Under the strategic agreement, Myosung will represent SINTX's interests within Korea in terms of identifying and cultivating prospective clients with interest in technical ceramic products & services. "Dr. Lee Boo Rak has a very well-known career background and excellent reputation within Korea. He has made significant contributions within several industries, including medical technology and robotics. We could not ask for a better partner to help us in our international expansion efforts," said Dave O'Brien, EVP & COO for SINTX. "We look forward to this partnership with Myosung and expect that it will generate significant new business for SINTX, particularly within the medical technology sector. The international markets are of growing importance for SINTX as we move forward."

08:51 EDT SEALSQ Corp. develops cybersecurity solution for EV charging stations - SEALSQ Corp announced that is has developed a comprehensive cybersecurity solution to enhance the security of Electric Vehicle charging stations. SEALSQ's innovative technology addresses the complex cybersecurity landscape associated with the growing infrastructure of EV charging stations and tackles known vulnerabilities that could compromise the integrity of the EV charging process. SEALSQ was recently selected by a major global electric appliances manufacturer, to secure their latest EV "Plug & Charge" stations.

08:49 EDT Mira announces DEA ruling on MIRA-55 as a not controlled substance - MIRA Pharmaceuticals announced that MIRA-55, has been determined by the U.S. Drug Enforcement Administration, or DEA, not to be a controlled substance or listed chemical under the Controlled Substance Act and its governing regulations. MIRA-55 is under investigation for treating adult patients suffering from neuropathic pain as well as anxiety and cognitive decline often associated with early-stage dementia. Unlike THC, which can impair cognitive function, MIRA-55 has demonstrated in pre-clinical studies that it can improve memory by 100% in wild-type mice. MIRA-55 has shown promising results in enhancing memory and cognitive performance in preclinical models. Unlike THC found in marijuana, which exhibits a biphasic effect, MIRA55 demonstrates a monophasic dose-response in pre-clinical models, indicating a more stable and consistent anti-anxiety effect across its dosage range. MIRA-55 exhibits lower potency at the CB1 receptor, which is responsible for the psychoactive effects of THC, while maintaining higher activation of the CB2 receptor. This suggests that MIRA-55 may deliver therapeutic benefits with minimal intoxicating effects.

08:49 EDT BTCS integrates with Forta to construct compliant Ethereum blocks - BTCS and the Forta Network announced an integration aimed at bolstering blockchain regulatory compliance. In January 2024, BTCS introduced Builder+, an Ethereum block builder. Builder+ utilizes advanced algorithms to maximize validator revenue by constructing optimized blocks for on-chain validation. BTCS believes Builder+ should enhance its Ethereum blockchain infrastructure and create opportunities for new growth. BTCS has incorporated Forta's AI-powered threat intelligence into Builder+, its Ethereum block-building operations. This sophisticated intelligence extends beyond merely screening wallet addresses on the OFAC Specially Designated Nationals list but also screens certain other tangentially connected or associated wallet addresses to enhance compliance and the detection of suspicious activities during the block construction phase.

08:47 EDT MannKind to in-license iSPERSE technology from Pulmatrix - MannKind Corporation (MNKD) has agreed to in-license iSPERSE technology from Pulmatrix (PULM) for certain indications in exchange for an out-license of MannKind's Cricket inhaler to Pulmatrix for inhaled delivery of dihydroergotamine for migraine treatment. The two companies also agreed that Pulmatrix will transfer its Bedford, Mass. R&D facility to MannKind, along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction. The royalty-free licensing structure will allow MannKind to have exclusive use of the iSPERSE technology for clofazimine, NTM, and insulin, and non-exclusive use for endocrine diseases and interstitial lung diseases including idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and other related lung diseases. In exchange, Pulmatrix will receive a royalty-free, exclusive license to MannKind's single-use Cricket inhalation device for inhaled delivery of DHE in any formulation and non-exclusive use for neurological diseases. MannKind expects to consolidate its Boston presence by transitioning its Marlborough staff into the newly renovated, fully outfitted R&D facility in Bedford. To maintain continuity of iSPERSE platform knowledge, MannKind plans to hire some members of current Pulmatrix R&D staff. The agreement is anticipated to close in July 2024.

08:42 EDT Wells Fargo CEO: Credit quality continues to remain 'very, very good'

08:40 EDT Jaguar Health executes out-license dal with JV Magdalena Biosciences - Jaguar Health (JAGX) announced that the company's out-licensing agreement with Magdalena Biosciences, the joint venture formed by Jaguar and Filament Health Corp. (FLHLF) to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded to cover ethnobotanical know-how related to development of a prescription drug compound from a specified medicinal plant for possible schizophrenia and psychoses indications and for development with potential corporate partners. "We are very happy to have executed the out-licensing arrangement with Magdalena related to the Botanical Drug Candidate," said Lisa Conte, Jaguar's president and CEO. "The amended license agreement between Jaguar and Magdalena stipulates that Jaguar will receive 10% of all upfront payments, milestone payments, and similar payments received by Magdalena as part of any business development partnerships Magdalena enters for the Botanical Drug Candidate, excluding commercial milestones and R&D reimbursements, up to a defined cap amount. The amended license agreement also stipulates that Jaguar will receive royalties on annual net sales of the Botanical Drug Candidate by Magdalena and any sublicensees, if the Botanical Drug Candidate receives FDA approval and is commercialized, with the royalty percentage increasing if annual net sales surpass a defined dollar amount." Neuropsychopharmacology profile analysis shows the Botanical Drug Candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms. Magdalena, which is approximately 40-percent owned by Jaguar, is focused on advancing plant-based innovation for patients and on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions. The Botanical Drug Candidate has a long history of use by traditional healers and may have the potential to be the first in a new class of plant-based antipsychotic compounds.

08:38 EDT BK Technologies receives two purchase order for BKR 5000 radios - BK Technologies Corporation announced that it has received two orders from the California Department of Forestry and Fire Protection totaling $9.1 million, for the purchase of BKR 5000 portable radios. These orders are a part of the agency's life cycle replacement program and represent a continuation of the migration from BK's KNG Series Portables. To date, CAL FIRE has purchased more than 6,500 BKR 5000 radios since they began the migration from the KNG Portable Series radio in 2022.

08:36 EDT HUB Security, BlackSwan jointly showcase advanced secured data fabric solution - HUB Cyber Security announces its joint participation with BlackSwan Technologies, BST, in the upcoming Money 20/20 event next week. Together, the strategic partners will demonstrate the cutting-edge Secured Data Fabric, SDF, solution, designed to facilitate secure access to data across multiple sectors. Noah Hershcoviz, CEO of HUB Cyber Security Ltd., commented, "We are excited to present our Secured Data Fabric solution at Money 20/20 with our partner, BST. This technology offers advanced protection and control over sensitive information, ensuring data security and integrity as industries rely more on data for their operations."

08:35 EDT Spectral AI set to join Russell Microcap Index - Spectral AI announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

08:34 EDT Reed's unveils new Virgil's 12oz can format in Sprouts Farmers Market - Reed's, Inc. (REED) announced the launch of Virgil's full sugar handcrafted sodas in a new, convenient 12oz can format for five classic flavors in Sprouts Farmers Market (SFM) nationwide.

08:33 EDT Artelo Biosciences presents data on solid dosage form of ART12.11 at CN-CANN24 - Artelo Biosciences announced Dr. Andrew Yates presented new pre-clinical data on ART12.11 at the CT-CANN24 conference which is being held May 29-30, 2024 at the Hilton London Canary Wharf in London, UK. The presentation, titled "An Aqueous Suspension of a Novel Cannabidiol: Tetramethylpyrazine Co-crystal, demonstrates a pharmacokinetic profile comparable with Epidiolex in Rats," highlights the Company's patented cocrystal of CBD and TMP, ART12.11, in an unoptimized formulation, demonstrated comparable pharmacokinetics of CBD and its metabolites to a mimic of Epidiolex, an FDA approved oral solution of CBD in ethanol and sesame oil used for controlling seizures in orphan childhood disorders with over $845 million in net sales for 2023. Oral solutions are commonly used for treating young children; however, for adolescents and adults a solid dosage form is preferred. A tablet form of ART12.11 is expected to be more attractive than an oral solution given its advantages in precise dosing, storage and transport.

08:32 EDT Onfolio subsidiary acquires First Page Strategy - Onfolio Holdings announced that its Subsidiary, RevenueZen LLC, has closed on an asset purchase agreement with First Page, a Washington limited liability company, whereby RevenueZen, acquired substantially all of First Page Strategy's business assets for a nominal cash down payment, with the remainder of the consideration being paid on a revenue share basis for the 36 months following the transaction close date. In addition, the First Page Strategy team will continue to serve their current strategist and leadership roles with the RevenueZen team.

08:28 EDT Johnson & Johnson reports seltorexant met endpoints in MDD3001 clinical trial - Johnson & Johnson announced topline results from the pivotal Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder, or MDD, with insomnia symptoms. Seltorexant is an investigational first-in-class selective antagonist of the human orexin-2 receptor being studied for the adjunctive treatment of MDD with insomnia symptoms. The findings will be presented at this year's American Society of Clinical Psychopharmacology, or ASCP, Annual Meeting, which is being held from May 28-31. The Phase 3 randomized, double-blind, multicenter, placebo-controlled study achieved all primary and secondary endpoints, with seltorexant demonstrating both a statistically significant and clinically meaningful improvement in depressive symptoms based on the Montgomery-Asberg Depression Rating Scale, or MADRS, total score at day 43, and improved sleep disturbance outcomes, in patients who had a prior inadequate response to SSRI/SNRI antidepressants alone. Additional data presented at ASCP includes positive topline results from the placebo-controlled Phase 4 TRD4005 study of SPRAVATO CIII nasal spray as a monotherapy in patients with TRD, which met both its primary and secondary endpoints. The randomized, double-blind, multicenter study showed SPRAVATO provided rapid, statistically significant, and clinically meaningful improvement in depressive symptoms ~24 hours after the first dose and sustained through 4 weeks of treatment, as assessed by changes in MADRS total score, J&J stated. Reference Link

08:26 EDT Stereotaxis announces first heart rhythm treatments at Penn Presbyterian - Stereotaxis announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, is the first in the Northeast United States to offer the Genesis System. Genesis is the latest advancement in Robotic Magnetic Navigation technology.

08:21 EDT Reinsurance Group CFO Todd Larson to switch roles, Axel Andre to succeed - Reinsurance Group announced that Axel Andre will join the company as executive VP on June 24. Following a brief transition period, effective August 5, the company expects to name Andre CFO, the role currently held by Todd Larson. Larson will transition into the role of special advisor to the CEO and will serve in that capacity until his retirement on December 31.

08:17 EDT VBI Vaccines announces new tumor response data from study of VBI-1901 in GBM - VBI Vaccines announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma or rGBM, patients. These data will be presented in a poster session at the 2024 American Society of Clinical Oncology ASCO Annual Meeting on Saturday, June 1... David E. Anderson, Ph.D., VBI's Chief Scientific Officer, said: "The tumor responses we have seen to date are incredibly encouraging, and, like the tumor responses did in the Phase 1/2a study, I am excited to see how this translates to clinical and survival outcomes later this year. The approved treatments for recurrent GBM patients have limited to no efficacy, which is consistent with the data seen in the standard-of-care arm in this study. VBI-1901's ability to stimulate an immune response capable of generating a disease control rate of 43% at this interim stage of the study, including a partial response, is hopefully an indication of the potential of this candidate to make a meaningful difference in the lives of patients, providers, and families."

08:15 EDT Nordic American Tankers 'clearly' sees 'strong demand' for vessels - In a shareholder letter, the company said, "Ninety day periods offer a short-term snapshot of a company, but it is also important to view the long-term picture. The values of our assets have seen a significant increase over the past years. The direction of NAT is unquestionably upward, with further room to grow. The first quarter of 2024 continued at a strong pace with healthy earnings. The Net Profit for the first quarter of 2024 came in at $15.1 million which is similar to the previous quarter with a Net Profit of $17.5 million. For the first quarter of 2024 the dividend is 12 cents per share. This is our 107th consecutive quarterly dividend. The dividend is payable July 18, 2024 to shareholders on record as of June 28, 2024. The average Time Charter Equivalent for our spot vessels during the first quarter of 2024 came in at $34,320 per day per ship. Including vessels on term contracts, the total average NAT TCE was $33,570 per day per ship. The daily operating costs per ship are about $9,000. Going forward, we clearly see strong demand for our vessels. The supply-demand dynamics in the market for the fleet of NAT are favorable. The NAT fleet of versatile suezmax tankers offer flexibility in loading and discharging ports. Through careful voyage planning and adjustment of speed of our vessels, we reduce emissions. Each individual ship in the NAT fleet is of excellent technical quality, as demonstrated in the vetting performance, the score board undertaken by the Oil Companies. NAT has one of the lowest debt levels among publicly listed tanker companies."

08:14 EDT Coda Octopus appoints McFadzean to board of directors - Coda Octopus announced the election of Dr. Angus McFadzean to fill a vacancy created by the recent decision of the Board to expand the number of seats on the Company's Board. His election will become effective July 1, 2024. Dr. McFadzean is one of the founders of Coda Technologies Limited in 1994 and has worked with its Marine Technology Business for the last 30 years.

08:12 EDT Genetic Technologies announces release of Comprehensive Risk Assessment test - Genetic Technologies announces the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman's risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease. Launched at the inaugural "Know Your Risk" event in California, USA, the event provided invaluable insights of the role of genomics in women's health. GTG's CEO, Simon Morriss, said "We are incredibly proud to have been part of this 'Know Your Risk' event which underscored the importance of genetic testing and risk assessment in transforming women's health, inspiring attendees to advocate for their health and well-being proactively. We are also very fortunate and to have the opportunity to launch this unique risk assessment test in the presence of such a wonderful group of people".

08:11 EDT CareDx reiterates position that it doesn't infringe '544 patent' - CareDx (CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, responded to Natera (NTRA) filing of a motion for an injunction related to patent 11,111,544..."We believe the motion against a process that is no longer in effect is irrelevant, and the District Court is still considering the fundamental question of the validity of the '544 patent," said John W. Hanna, CareDx President and CEO. "We greatly appreciate the continued support of the transplant community as we seek to resolve these matters, allowing us to return our full attention to serving patients and developing clinical innovations that improve transplant care." Natera has previously claimed infringement on three patents:

08:11 EDT Aeon announces strategic resource reprioritization, cuts workforce by 55% - AEON Biopharma announced a strategic reprioritization and cost reduction plan as the Company evaluates all financing options to support next steps across its late-stage clinical pipeline for ABP-450 that targets multiple indications. The Company's actions are expected to be sufficient to extend its cash runway into the fourth quarter of 2024. As part of the cash preservation strategy, AEON has reduced its workforce by approximately 55%. This includes the Company's termination of Peter Reynolds as the CFO, principal financial officer and principal accounting officer, effective as of May 17, 2024. Concurrently, the Board appointed Mr. Forth as principal financial officer and Jennifer Sy, the Company's corporate controller, as principal accounting officer, each effective as of May 17, 2024. Mr. Forth and Ms. Sy will continue in their prior roles. These cost reduction actions will also include efforts to reduce additional operating costs and are expected to be substantially completed by June 2024.

08:09 EDT Indaptus Therapeutics to present new cohort data on Phase 1 trial of Decoy20 - Indaptus Therapeutics announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented. In the abstract, titled, "Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors," investigators continued to provide validation from early results of the single dose cohort of its Phase 1 clinical trial. The data presented include the pharmacokinetics and immune response observed in both cohorts in the ongoing Phase 1 trial for Decoy20. A single i.v. dose of Decoy20 disappeared from blood within 30-120 minutes and produced transient induction in plasma of over 50 cytokines and chemokines, many of which have been associated with stimulation of innate and/or adaptive immune responses. These findings are important components of the "pulse-prime" hypothesis for Decoy20's anti-tumor effect.

08:08 EDT DZS announces customer Tachus ranked leader for broadband service - DZS announced that its longtime customer, The Woodlands-based Tachus Fiber Internet was recognized as the top broadband experience provider in the Southwestern U.S. in OPENSIGNAL's USA Fixed Broadband Experience Report, which ranked Tachus as the leader in every category it measures, including Broadband Consistent Quality, Broadband Video Experience and Broadband Download and Upload Speeds. "We are proud to deliver the best broadband performance and quality of experience in our region to our rapidly growing customer base and boast among the fastest internet speeds in the region powered by DZS and its world-class fiber access technology," said Hal Brumfield, Founder and CEO, Tachus. "The stability, flexibility, and capabilities of DZS solutions are second-to-none and their attentiveness and support make them an invaluable partner. As DZS continues to innovate, we plan to leverage their leadership to take our network to new levels, expand our competitive edge and take market share by delivering a superior broadband experience."

08:07 EDT Kraft Heinz Canada, Highbury Canco extend partnership in Leamington - Kraft Heinz Canada and Highbury Canco announced the extension of their partnership agreement in Leamington for another four years, with the production deal now in place until the end of 2027. This announcement marks the third consecutive extension in the longstanding partnership between the two organizations in Southern Ontario, a connection that has served to support jobs and bolster the local economy. Highbury Canco employs more than 600 Canadians at its 2.1-million-square-foot facility in Leamington, where it produces some of Kraft Heinz Canada's most beloved products, including Heinz beans, Heinz tomato juice and Classico pasta sauce. Kraft Heinz Canada, the country's second largest food manufacturer, is excited to extend the partnership with Highbury Canco to ensure many of its locally sourced products will continue to be produced in Leamington for years to come. The estimated retail value of Kraft Heinz Canada products that will be produced at Highbury Canco's Leamington facility over the next four years exceeds $1B.

08:07 EDT Ayr Wellness partners with Kowloon Restaurant to launch limited edition seltzer - AYR Wellness announced LEVIA, the Company's brand of cannabis-infused seltzers and tinctures, has partnered with the iconic Kowloon Restaurant, the Boston area's landmark Asian restaurant and entertainment destination, to launch a new limited edition cannabis-infused seltzer. The LEVIA Kowloon Mai Tai seltzer pays homage to Kowloon's famous Mai Tai cocktail while elevating summer's warm, sunny days with a fast-acting, expertly formulated infused beverage bursting with vibrant, all-natural flavor.

08:06 EDT Optimi Health secures import permit from Mind Medicine Australia - Optimi Health (OPTHF) has received an import permit from Mind Medicine Australia (MNMD) to export its GMP MDMA and psilocybin capsules to supply approved psychiatrists under Australia's Authorised Prescriber Scheme. Mind Medicine Australia, a partner with Optimi since February 2023, achieved a world-first last year by successfully advocating for the rescheduling of MDMA for the treatment of PTSD and psilocybin for treatment-resistant depression. As a result, these medicines are now available to Authorised Prescribers in Australia, paving the way for groundbreaking therapeutic options this year. To further support this initiative, Optimi has developed a secure Prescriber Portal set to launch in June 2024 to a network of more than 2,800 Australian psychiatrists. This tool will provide psychiatrists and practitioners with pre-authorized access to comprehensive information on the import and export process, as well as detailed insights into Optimi's MDMA and psilocybin capsules.

08:05 EDT BioNTech, CEPI expand partnership to strengthen Africa's mRNA vaccine ecosystem - BioNTech and the Coalition for Epidemic Preparedness Innovations, CEPI, are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem. CEPI is committing up to US $145 million to support BioNTech to establish mRNA vaccine R&D, clinical and commercial-scale manufacturing capabilities at the Company's facility in Kigali, Rwanda. These capabilities will contribute to efforts to better prepare for potential future epidemic and pandemic threats in Africa. BioNTech's commercial-scale manufacturing facility in Kigali was first announced in 2021 and inaugurated in December 2023. The facility is based on the Company's high-tech, digitally enabled modular manufacturing units called BioNTainers, designed to manufacture a range of mRNA-based vaccines. BioNTech's Kigali manufacturing facility could become the first commercial mRNA facility in Africa, intended to support the African Union's and Africa CDC's goal of producing 60 percent of total vaccine doses required on the continent by 2040.

08:04 EDT Akili to go private through merger agreement with Virtual Therapeutics - Virtual Therapeutics and Akili announced the signing of a definitive merger agreement to form a diversified digital health company. Under the terms of the agreement, Akili shareholders will receive $0.4340 per share of common stock in cash. The per share purchase price represents an approximately 4% premium to Akili's closing stock price on May 28 and an approximately 85% premium to Akili's closing price on April 29, the last trading day prior to Akili's public announcement that it was evaluating potential strategic alternatives. Following completion of the transaction, the combined organization will operate as Virtual Therapeutics, a privately held company, with Akili operating as a wholly owned subsidiary. The transaction, approved by both of Virtual Therapeutics' and Akili's board of directors, is expected to close in the third quarter of 2024, subject to certain closing conditions, including the tender of a majority of Akili shares into a tender offer to be launched by Virtual Therapeutics and Akili having not less than a specified amount of cash-on-hand, depending on the closing time. The transaction is not subject to a financing condition. Upon completion of the transaction, Akili's common stock will no longer be listed on any public stock exchange.

08:04 EDT Clear Secure opens in several new locations - Clear, an authorized TSA Pre-Check enrollment provider, continues to expand locations to enroll and renew consumers in the Trusted Traveler program by opening new locations at the following: Milwaukee Mitchell International Airport (MKE), Los Angeles International Airport (LAX), Harry Reid International Airport (LAS), Birmingham Shuttlesworth International Airport (BHM), San Diego International Airport (SAN), Ronald Reagan Washington National Airport (DCA), and John F. Kennedy International Airport (JFK).

08:03 EDT Integral Ad Science expands reporting and insights for Amazon DSP media buys - Integral Ad Science (IAS) announced its expanded reporting and insights are now available for Amazon DSP media buys. Through a server-to-server, or S2S, integration on Amazon (AMZN) DSP, advertisers will now have access to measurement coverage for campaigns across Amazon custom audiences and Twitch inventory. IAS's solutions available to advertisers in Amazon DSP include viewability, invalid traffic (IVT), and brand safety and suitability. IAS now provides Amazon DSP media buyers with brand safety and suitability, viewability, and IVT measurement on custom audiences and Twitch; cross-device measurement for web and in-app across CTV, mobile, desktop, and tablet; IAS's Brand Safety & Suitability, Viewability, and Invalid Traffic measurement expansion with Amazon Ads will be available in IAS Signal, designed to provide advertisers with greater access to campaign data and a unified view of their global campaigns.

08:00 EDT Biohaven reports data from Phase 1 SAD study of BHV-1300 - Biohaven unveiled new positive data from its ongoing Phase 1 single ascending dose, or SAD, study with BHV-1300, a first-in-human IgG degrader that uses an ASGPR-bispecific from its MoDE platform. Emerging results in healthy subjects confirm that BHV-1300 rapidly and selectively lowers IgG in a dose-dependent manner in the first 4 cohorts completed to date. Preliminary IgG lowering data is consistent with modeling, with dose- and time-dependent IgG lowering observed even in initial low-dose cohorts. Some subjects experienced IgG reductions as low as 50 to 70% of baseline. BHV-1300 demonstrated reduction of IgG without significantly impacting LFTs, albumin, LDL cholesterol or other serum labs. BHV-1300 has been safe and well tolerated to date, with no serious or severe adverse events. Most AEs were mild, deemed unrelated to study drug and resolved spontaneously. As expected from the selectivity of the molecule for IgG, when compared to placebo, there were no meaningful reductions in average IgA, IgM or IgE levels during the week after dosing. No adverse trends have been observed in vital signs or ECGs. Given the levels of IgG lowering observed to date, the company plans to evaluate approximately 6 cohorts of BHV-1300. Modeling suggests additional cohorts in the Phase 1 study will achieve greater than 70% lowering of IgG utilizing doses compatible with subcutaneous administration. Given the promising results of the SAD study thus far, the MAD study will proceed in patients with rheumatoid arthritis.

07:51 EDT Biohaven provides overview of advances across multiple therapeutic areas - Biohaven provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's senior management team and key opinion leaders will share updates with investors and research analysts. The clinical progress, regulatory updates and pipeline developments at Biohaven's R&D Day include: Molecular Degrader of Extracellular Proteins, or MoDE, Platform; Ion Channel Platform; Myostatin Program; Neuroinflammation Platform; Glutamate Modulating Platform; and Oncology Platform. Vlad Coric, Chairman and CEO of Biohaven, commented on the Company's 2024 R&D Day: "Biohaven is leading the way in immune modulation with our first of its kind mechanism of action in MoDE degraders advancing through the early cohorts of Phase 1 testing. Equally important and exciting is that these data provide clinical validation for Biohaven's MoDE degrader platform, which represents an entirely novel class of drugs with rapid development timelines and unlimited clinical and commercial potential. The platform can efficiently generate compounds designed to selectively degrade a specific extracellular protein of interest, such as an individual disease-causing autoantibody. The advancement of BHV-1300 has accelerated the development of other assets from the MoDE platform. We anticipate delivering approximately ten clinical-stage degraders over the next three years with the goal of radically transforming the treatment of a broad range of diseases, including up to three additional compounds by the end of this year. This technology has the potential to transform the treatment of autoimmune disorders and disrupt current treatment paradigms across therapeutic areas."

07:47 EDT Jacobs selected by Los Angeles World Airports - Jacobs is one of 15 lead consultants selected by Los Angeles World Airports, or LAWA, to provide on-call, task order-based, professional services through a Multiple Award Task Order Contract, or MATOC. The work will support initiatives relating to LAWA's Capital Improvement Program and modernizations at Los Angeles International Airport, or LAX, and Van Nuys Airport, or VNY. LAWA's program services MATOC is the largest award of its kind in the City of Los Angeles' history, breaking inclusivity records and setting new standards for local, diverse, veteran, small and microbusiness participants. Allied with LAWA's efforts, Jacobs will engage local minority businesses on its respective task orders, including support from more than 30 small diverse business partners, which could provide opportunities for small and disadvantaged business growth for years to come.

07:36 EDT CTO Realty Growth corrects ex-dividend date for Q2 dividend - CTO Realty Growth announced a correction to the ex-dividend date previously announced on May 28, 2024. The ex-dividend date for the second quarter dividends payable on the Company's common stock and Series A Preferred Stock has been corrected from June 12, 2024 to June 13, 2024.

07:34 EDT Buckley Capital urges Dentalcorp board to undertake strategic review process - Buckley Capital Management,which together with its affiliates beneficially owns approximately 1.4% of the shares of Dentalcorp Holdings, issued an open letter to DNTL's board of directors and management urging them to launch a strategic review process to maximize value for all shareholders. The letter read in part, "Dentalcorp has executed well in the 18 months since our initial investment in the Company. However, its stock has languished and dramatically underperformed peers. We are concerned that the public markets will continue to undervalue the Company's shares going forward, causing irreparable harm to the long-term value of the business. Based on our analysis of private dental roll ups and other public peers with similar financial metrics, we believe the Company could be worth $12-$16/share to a private market buyer today, providing shareholders with a significant premium to current prices. In our view the Company's prior strategic review process, which started in late 2022 and ended in mid-2023 without a sale, likely failed due to the March 2023 banking crisis and frozen credit markets, which made it nearly impossible to consummate a deal. Given the financing environment has improved significantly since then, we believe the Company is in a strong position to consummate a transaction in today's market. Therefore, the Board should immediately commence a strategic review process to maximize value for shareholders, including exploring a sale of the Company. Dentalcorp is significantly undervalued by the public markets relative to the quality and predictability of its future growth. The differences in valuation multiples between the Company and its private and public peers are even more striking given the improved interest rate outlook, the Company's predictable growth profile, and prospects for future margin expansion...Additionally, the Company's shares are currently trading below liquidation value of its practices. In the Bank of America Securities Healthcare Conference just a few weeks ago, the Company's CFO stated that "if we look at the entirety of our practice space of our 550 clinics, break them up and sell them at market value of 7.5x practice level EBITDA, we would be at roughly call it $10.00 to $10.50 per share." We believe there is clearly significant platform value given where the peers trade, so DNTL should trade above that level. The DNTL CFO then went on to explain "as the process unfolded from October 2022-March 2023, there was significant unrest in the credit markets. Silicon Valley Bank went down, and the floor of the credit market fully fell out. As we looked at it from a value perspective, and as the board was evaluating the opportunities before them it was not a value issue, what it truly was, was a credit issue." Given the credit markets are in a significantly better place today than they were during the banking upheaval in March 2023, we believe that the right value would be achieved today by exploring strategic alternatives. The dramatic undervaluation of the Company impairs its ability to issue shares for financing acquisitions and incentive compensation. More importantly, the longer this dynamic sustains, the more permanent the damage becomes given DNTL is the only publicly traded DSO and thus has no perfect public comparable companies. We strongly encourage the Board to engage a financial advisor immediately to pursue a review of strategic alternatives, including the sale of the Company. We aim to work collaboratively and constructively with the Board and management to maximize shareholder value, and look forward to continued positive dialogue."

07:33 EDT AST SpaceMobile, Verizon partner on direct-to-cellular AST SpaceMobile service - AST SpaceMobile (ASTS), and Verizon (VZ) announced a strategic partnership with a commitment of $100M from Verizon, to provide direct-to-cellular AST SpaceMobile service when needed for Verizon customers. The combination of Verizon's terrestrial mobile network, the multi-operator 850 Mhz band and the commercial communications arrays ever deployed in low Earth orbit, is planned to enable cellular consumers to stay connected in the continental United States. The $100M Verizon commitment includes $65M of commercial prepayments, $45M of which are subject to certain conditions, and $35M of convertible notes. AST SpaceMobile has agreements with more than 45 mobile network operators globally who collectively serve over 2.8 billion existing subscribers.

07:32 EDT Streamline Health announces new RevID contract with 400-bed health system - Streamline Health announced that it has signed a new contract for the use of RevID, with a 400-bed, Oracle Cerner-EHR based health system with facilities in Southern California. The deal was closed in partnership with Oracle. "We are thrilled to support another key health system through our Oracle Health partnership," stated Ben Stilwill, President and Chief Executive Officer, Streamline. "We look forward to continued expansion of our client footprint through our direct and partnership channels in fiscal 2024."

07:22 EDT Origin Materials and Bachmann Group to mass produce PET caps and closures - Origin Materials and Bachmann Group a packaging production and logistics company, announced a strategic partnership to mass produce PET caps and closures. In Bachmann's existing world-class European manufacturing facilities, Bachmann and Origin will operate the lines to convert virgin and recycled PET into caps, including tethered caps, using high-speed equipment and automation. Origin's caps are positioned to be the first commercially viable PET closures to reach the mass market. "Today we are announcing our partnership with Bachmann Group, who will assist in the end-to-end operation and automation of our PET cap mass production lines," said Origin Co-CEO and Co-Founder John Bissell. "Bachmann Group will help us produce billions of caps, taking pellet or flake all the way to finished closures. We share a commitment to sustainability and look forward to a productive partnership."

07:21 EDT Jeito Capital announces acquisition of portfolio company EyeBio by Merck - Jeito Capital announced that its portfolio company EyeBiotech, a privately held clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for sight-threatening eye diseases, and Merck & Co have entered into a definitive agreement under which, Merck & Co, through a subsidiary, will acquire EyeBio. Under the terms of the agreement, Merck & Co, through a subsidiary, will acquire all outstanding shares of Eyebio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and commercial milestone payments. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2024. EyeBio is developing a pipeline of clinical and preclinical stage candidates for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal disease. Jeito first invested in EyeBio in February 2022, just one year after its creation, as co-lead investor of a $65 million series A funding. In November 2023, Jeito participated again in EyeBio's $65 million extension of its series A financing, in line with Jeito's refinancing strategy to support portfolio companies with a significant deployment of capital at every value milestone reached. These financing rounds were made alongside other major investors in the life sciences industry: SV Health Investors, Samsara BioCapital, MRL Ventures, Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC.

07:18 EDT Blackstone Real Estate to sell Turtle Bay Resort for $725M - Blackstone Real Estate announced that it has reached an agreement to sell Turtle Bay Resort for $725M, Blackstone purchased the hotel in 2018 for $332M and subsequently invested significant capital in renovations....The sale is expected to close in the third quarter of 2024. In a separate transaction, Arete Collective, a vertically integrated development company known for sustainable development practices that prioritize climate resilience, announced the closing of a transaction to purchase 65 acres of land at Turtle Bay on O'ahu's North Shore. Inclusive of the recent land sale to Arete and following the close of the property sale transaction, sale proceeds generated on the hotel by Blackstone will total $768M.

07:17 EDT Biohaven doses first patient in Phase 1/2 study of BHV-1510 - Biohaven announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 directed Antibody Drug Conjugate, or ADC, and the lead ADC program to advance into clinical trials in Biohaven's growing oncology pipeline. The Phase 1/2 study of BHV-1510 is a multicenter, open-label study in subjects with select advanced or metastatic epithelial cell tumors. The trial consists of a dose-escalation phase, followed by a multicohort expansion phase. BHV-1510 is a next-generation, fully optimized ADC that consists of a Trop-2 directed antibody conjugated to a proprietary best-in-class Topoisomerase 1 payload at a homogeneous drug-antibody ratio of 4. BHV-1510 incorporates a unique site-specific conjugation methodology and highly stable and irreversible linker chemistry designed by GeneQuantum Healthcare

07:15 EDT ScaleReady launches $20M G-Rex Grant Program - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne and CellReady, announced the launch of the G-Rex Grant Program, a $20M initiative to propel the advancement of cell and gene therapies. The G-Rex Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the material resources and services needed to implement or optimize a highly efficient G-Rex(R) based cell manufacturing platform. Qualifying programs can receive up to $300,000 in G-Rex devices, critical reagents, capital equipment, application support, and manufacturing consultation services. G-Rex Grants will be awarded to applicants that provide a compelling overview of why a G-Rex Grant would be beneficial, a strong willingness to work collaboratively to achieve program goals, a demonstrated track record of successful program management, and a provision of well understood deliverables.

07:14 EDT Surmodics to be acquired by PE firm GTCR for $43 per share in cash - Surmodics announced that it has entered into a definitive agreement to be acquired by GTCR, a private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627M. The per-share acquisition price represents a 41.1% premium to Surmodics' 30-trading day volume-weighted average closing price through May 28 . Surmodics' Board of Directors has unanimously approved the transaction and resolved to recommend that stockholders vote in favor of the transaction...The transaction is expected to close in the second half of calendar year 2024, subject to customary closing conditions, including approval by Surmodics shareholders and required regulatory approval. It will be financed through a combination of committed equity from funds affiliated with GTCR and committed debt financing. Upon completion of the transaction, Surmodics will be a privately held company and its common stock will no longer be listed on The Nasdaq Stock Exchange.

07:12 EDT Chewy announces $500M share repurchase program - Chewy also announced that its board of directors has authorized a share repurchase program of up to $500M of its Class A and/or Class B common stock.

07:11 EDT Dick's Sporting jumps 8% to $210.50 after Q1 results beat, FY24 guidance raised

07:10 EDT Aethon to acquire Tellurian's integrated upstream assets for $260M - Tellurian and Aethon Energy Management or Aethon, announced an agreement for Aethon to acquire Tellurian's integrated upstream assets for $260M , alongside a Heads of Agreement for Aethon to purchase two million tons per annum or mtpa, of liquified natural gas LNG from Tellurian's Driftwood LNG plant. The assets will expand Aethon's footprint in the Louisiana Haynesville and Bossier shale basins with approximately 31,000 net acres, including gathering and treating systems that have capacity for up to 100Mcubic feet per day that will bring Aethon's pro forma gathering and treating capacity to over 3 Bcf/d across its assets... The transaction is expected to close during the second quarter of 2024, and Tellurian will use the proceeds to reduce borrowings and for general corporate purposes. Tellurian Executive Chairman Martin Houston said, "Today's agreements with Aethon take us several steps closer to developing the Driftwood LNG project, for which Aethon is a vital partner. The offtake agreement for two mtpa provides the foundation to accelerate Driftwood and demonstrates that we have successfully aligned our commercial offerings to meet the needs of potential customers. For Tellurian, the proceeds from the sale of our upstream assets allow us to retire senior secured notes and strengthen our balance sheet for the long term. "

07:10 EDT Aethon to acquire Tellurian's integrated upstream assets for $260M - Tellurian and Aethon Energy Management or Aethon, announced an agreement for Aethon to acquire Tellurian's integrated upstream assets for $260M , alongside a Heads of Agreement for Aethon to purchase two million tons per annum or mtpa, of liquified natural gas LNG from Tellurian's Driftwood LNG plant. The assets will expand Aethon's footprint in the Louisiana Haynesville and Bossier shale basins with approximately 31,000 net acres, including gathering and treating systems that have capacity for up to 100Mcubic feet per day that will bring Aethon's pro forma gathering and treating capacity to over 3 Bcf/d across its assets... The transaction is expected to close during the second quarter of 2024, and Tellurian will use the proceeds to reduce borrowings and for general corporate purposes. Tellurian Executive Chairman Martin Houston said, "Today's agreements with Aethon take us several steps closer to developing the Driftwood LNG project, for which Aethon is a vital partner. The offtake agreement for two mtpa provides the foundation to accelerate Driftwood and demonstrates that we have successfully aligned our commercial offerings to meet the needs of potential customers. For Tellurian, the proceeds from the sale of our upstream assets allow us to retire senior secured notes and strengthen our balance sheet for the long term. "

07:09 EDT Assertio Holdings appoints O'Grady as new CEO - Assertio Holdings announced that its Board of Directors has appointed Brendan O'Grady as the Company's new Chief Executive Officer and a member of the board, effective today, May 29, 2024. Most recently, O'Grady was CEO of the Global Formulations business at Glenmark Pharmaceuticals, driving new product launches and focused on growing profitability in key markets.

07:08 EDT ConocoPhillips to increase dividend by 34% to 78c per share - Independent of the transaction, ConocoPhillips expects to increase its ordinary base dividend by 34% to 78 cents per share starting in the fourth quarter of 2024. Upon closing of the transaction and assuming recent commodity prices, ConocoPhillips plans to repurchase over $7B in shares in the first full year, up from over $5B standalone. In addition, repurchase over $20B in shares in the first three years.

07:08 EDT OTC Markets Group welcomes Marpai to OTCQX - OTC Markets Group announced Marpai, an independent national Third-Party Administration company, has qualified to trade on the OTCQX Best Market. Marpai, Inc. previously traded on NASDAQ.

07:07 EDT Milestone Pharmaceuticals announces FDA acceptance of NDA for CARDAMYST - Milestone Pharmaceuticals announced that the United States Food and Drug Administration, FDA, accepted the Company's New Drug Application, NDA, on May 26, 2024 for CARDAMYST nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia, PSVT. The FDA Prescription Drug User Fee Act, PDUFA, target date is 10 months from the acceptance date of May 26, 2024. "The FDA's acceptance of our NDA for CARDAMYST brings Milestone one step closer in our mission in providing a new, convenient and effective treatment option for patients with PSVT," said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals. "We understand the frequent impact that PSVT has on patients, as well as the underappreciated burden it places on their families and caregivers. Our progress toward providing a sense of security for patients is a result of the dedicated Milestone team, patients, and investigators to whom we are thankful."

07:06 EDT PMV Pharmaceuticals, Foundation Medicine announce collaboration - Foundation Medicine and PMV Pharmaceuticals announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOneCDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. "The innovative science driven by PMV Pharma's efforts specific to TP53 Y220C has the potential to offer a new therapeutic option for patients in this area of high unmet medical need," said Troy Schurr, Chief Biopharma Business Officer at Foundation Medicine. "We're proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option."

07:05 EDT Immunocore converts Phase 2/3 TEBE-AM trial into registrational Phase 3 trial - Immunocore announced that the TEBE-AM Phase 2/3 clinical trial has been converted into a Phase 3 trial. The Phase 2/3 TEBE-AM trial was designed to evaluate KIMMTRAK, as monotherapy and in combination with pembrolizumab, versus a control arm, for the treatment of patients with previously treated advanced cutaneous melanoma. The registrational TEBE-AM trial was initiated following results from a Phase 1b trial of tebentafusp in combination with checkpoint inhibitors in metastatic cutaneous melanoma. The Phase 1b data showed that the maximum target doses of tebentafusp plus durvalumab were well tolerated, and that, in mCM patients who progressed on prior anti-PD(L)1, the combination demonstrated a one-year overall survival rate of ~75%.

07:04 EDT Host Hotels enters into agreement to acquire Turtle Bay Resort in Hawaii - Host Hotels & Resorts announced that it entered into an agreement to acquire the fee simple interest in the 450-room Turtle Bay Resort on the North Shore of Oahu, Hawaii, including a 49-acre land parcel entitled for development, for approximately $680 million, net of key money. The purchase price allocation is expected to be $630 million for the Resort and $50 million for the Land Parcel, subject to final appraisal. The acquisition price represents a 16.3x EBITDA multiple or a cap rate of approximately 5.3% on the Resort's 2024 estimated results1. The purchase is subject to customary closing conditions and the transaction is expected to close in late July of 2024. James Risoleo, President and Chief Executive Officer, said, "We are thrilled to enter into an agreement to acquire Turtle Bay Resort, which will further expand and diversify our already strong presence in Hawaii. Oahu is a high demand leisure destination with consistently high occupancy, an internationally diverse demand base, and high barriers to entry, resulting in slightly negative supply growth historically and essentially no anticipated near-term supply. In addition, because of the Resort's recent transformational renovation, we do not expect meaningful capital expenditures in the near term. We look forward to working with employees and local partners to build upon the Resort's preeminent position on the North Shore of Oahu. With the planned Ritz-Carlton rebranding, we believe the Resort will generate outsized growth as it stabilizes, further elevating the EBITDA growth profile of our portfolio."

07:04 EDT Bristol Myers announces EC approves Opdivo combination - Bristol Myers Squibb announced that the European Commission, or EC, has approved Opdivo, or nivolumab, in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma, or UC. With this approval, Opdivo in combination with cisplatin and gemcitabine becomes the first concurrent immunotherapy-chemotherapy approved for the treatment of adult patients with unresectable or metastatic UC in the first-line setting in the European Union. The EC's decision is based on results from the CheckMate -901 trial studying Opdivo in combination with cisplatin and gemcitabine, which were presented at the European Society of Medical Oncology, or ESMO, Congress 2023. In CheckMate -901, Opdivo in combination with cisplatin and gemcitabine followed by Opdivo monotherapy demonstrated statistically significant and clinically meaningful improvements in the primary efficacy endpoints of overall survival, or OS, and progression-free survival, or PFS, compared to chemotherapy alone, as assessed by Blinded Independent Central Review, or BICR. The safety profile was consistent with the known safety profiles of the individual components of the regimen. No new safety concerns were identified. Opdivo in combination with cisplatin and gemcitabine reduced the risk of death in patients by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with cisplatin-gemcitabine alone. Risk of disease progression or death reduced by 28%, with a median PFS of 7.9 months compared to 7.6 months with cisplatin-gemcitabine alone.

06:56 EDT Aecom awarded contract from the U.S. Army Environmental Command - AECOM announced that it has been awarded a five-year, multiple-award contract from the U.S. Army Environmental Command to provide environmental remediation services, including investigation and remediation services for per- and polyfluoroalkyl substances, or PFAS, at various locations throughout the contiguous United States, Puerto Rico, Hawaii and Alaska. AECOM's scope encompasses the investigation and remediation hazardous and toxic waste throughout the United States, including persistent compounds such as PFAS. With more than two decades of PFAS experience at more than 600 sites globally, AECOM is uniquely suited to support the U.S. Department of Defense PFAS responses.

06:50 EDT Terran Orbital announces key appointments to executive team - Terran Orbital announced key appointments to its executive team aimed at accelerating the Company's path to driving revenue growth and becoming free cash flow positive. The Company welcomes Peter Krauss as its new COO, Adarsh Parekh as its new CFO, and Mathieu Riffel as its Chief Accounting Officer. The appointment of Krauss is effective as of June 1 and the appointments of Parekh and Riffel are effective as of June 17. Krauss and Parekh will each report to Marc Bell, the Company's Co-Founder, Chairman, and CEO. Upon the effectiveness of Parekh and Krauss's appointments, respectively, Riffel will report to Parekh. Krauss will oversee all engineering, manufacturing, supply chain, business development, and marketing functions, as well as our international operations. Parekh will oversee all accounting, finance, and investor relations functions. Tony Gingiss, the Company's current COO, has decided to leave Terran Orbital. This decision comes from a place of mutual respect and understanding. Gingiss has agreed to provide strategic advisory services to the Company until his departure on July 15. As COO, Peter Krauss will focus on enhancing operational efficiency and reducing costs across Terran Orbital's manufacturing and production processes. Krauss is a seasoned Sales, Marketing, and Operational executive with nearly 30 years of experience driving organizational growth and profitability, as well as extensive expertise in building and managing complex, global manufacturing and distribution systems. Krauss brings a wealth of expertise in cost reduction, process optimization, and efficiency improvement. Adarsh Parekh joins Terran Orbital as CFO, bringing over 20 years of experience in the financial sector, including in strategic growth initiatives, strategic planning and implementation, FP&A, M&A, leveraged finance, capital markets transactions, and treasury management. Prior to joining Terran Orbital, Parekh served as CFO of Alio, a medical technology company, where he oversaw all finance and accounting functions and was a key contributor to the company's initial commercialization efforts. As CAO, Mathieu Riffel will focus on the Company's accounting, financial reporting, internal controls, and compliance processes. Mathieu Riffel has worked for the Company since 2021, most recently serving as Acting CFO.

06:48 EDT Merck to acquire EyeBio for $1.3B upfront payment - Merck and Eyebiotech, a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio. Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of EyeBio for up to $3B, including an upfront payment of $1.3B in cash and a further potential $1.7B in developmental, regulatory and commercial milestone payments. The acquisition has been unanimously approved by the EyeBio Board of Directors. EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases. The company's lead candidate, Restoret (EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway. Based on positive results from the open-label Phase 1b/2a AMARONE study in patients with diabetic macular edema and neovascular age-related macular degeneration, Restoret is anticipated to advance into a pivotal Phase 2b/3 trial to investigate the treatment of patients with DME in the second half of 2024. Closing of the proposed acquisition is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2024 and be accounted for as an asset acquisition. Merck expects to record a charge of approximately $1.3B, or approximately 50c per share, that will be included in non-GAAP results in the quarter that the transaction closes.

06:44 EDT Cellectar Biosciences announces partnership with City of Hope Cancer Center - Cellectar Biosciences announced a strategic partnership with City of Hope Cancer Center, one of the largest cancer research and treatment organizations in the U.S. The collaboration will focus on the clinical development of Cellectar's lead radioconjugate asset, iopofosine I 131, in mycosis fungoides, or MF, a rare form of non-Hodgkin's lymphoma, or NHL, that affects the skin and, in some patients, internal organs and blood. Iopofosine is the first systemic targeted radiotherapeutic to be assessed for cutaneous T-cell lymphomas, or CTCL. The investigator sponsored trial will evaluate approximately 10 patients; initiation is planned for late 2024 or early 2025. MF has a prevalence of approximately 30,000 patients and is the most common form of CTCL. It is a slow-growing form of blood cancer in which some of the body's white blood cells become malignant and has no curable treatment options. The FDA has granted iopofosine I 131, a small-molecule Phospholipid Drug Conjugate, or PDC, designed to provide targeted delivery of iodine-131, or radioisotope, Orphan Drug and Fast Track Designation for relapsed/refractory Waldenstrom's macroglobulinemia, r/r multiple myeloma and r/r diffuse large B-cell lymphoma. Cellectar is preparing to submit a New Drug Application to the FDA based on its CLOVER WaM pivotal study in WM in the second half of 2024. The company previously announced topline data from its CLOVER WaM pivotal study earlier this year and plans to announce updated results in June.

06:33 EDT Advance Auto Parts backs FY24 CapEx view $200M-$250M

06:08 EDT Bank of Montreal increases quarterly dividend 3% to C$1.55 per share - Bank of Montreal announced at its board of directors declared a quarterly dividend of C$1.55 per share on paid-up common shares of Bank of Montreal for the third quarter, a 4c, or 3%, increase from the prior quarter, up 5% from the prior year.

05:38 EDT Arrowhead announces results from ARCHES-2 study - Arrowhead announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia. Zodasiran was associated with reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation at the European Atherosclerosis Society, or EAS, 92nd Congress and simultaneously published in the New England Journal of Medicine. Zodasiran treatment was associated with dose-dependent placebo adjusted reductions in triglycerides, remnant cholesterol, LDL-C, ApoB, and Non-HDL-C across all dose levels in patients with mixed hyperlipidemia. At week 24, representing trough effect, zodasiran treatment at 50, 100, and 200 mg on day 1 and week 12 was associated with placebo adjusted reductions in triglycerides of -51%, -57%, and -63% respectively. ANPTL3, the genetic target of zodasiran, was reduced compared with placebo by -54%, -70%, and -74%, and remnant cholesterol levels were reduced by -73%, -76%, and -82%, which correlated with changes in triglyceride levels. Changes in other atherogenic lipoprotein parameters were also observed across all three dose levels. At week 24, the following placebo adjusted changes were observed for the 200 mg dose: LDL-C -20%, ApoB -22%; Non-HDL-C -36%. In a subset of patients with baseline liver fat fraction greater than 8%, dose-dependent liver fat reductions, measured by MRI-PDFF, were observed reaching -28% with the 200 mg dose compared with -2% with placebo. Zodasiran demonstrated a favorable safety profile in patients with mixed hyperlipidemia in the ARCHES-2 study. Treatment-emergent adverse events, or TEAEs, were generally balanced between treatment and placebo groups and generally reflected the comorbidities and underlying conditions of the study population. There were no clinically meaningful changes in laboratory safety evaluations, no changes in mean platelet counts, and modest changes in HbA1c.

05:26 EDT Genentech announces FDA priority review for inavolisib - Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company's new drug application and granted priority review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor, or HR-positive, human epidermal growth factor receptor 2, or HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.

05:21 EDT Lilium expands partnership with Luxaviation Group - Lilium announced an expansion of its partnership with Luxaviation Group, one of the largest business aircraft and helicopter operators worldwide. The company said the expansion will unlock and leverage ExecuJet's network of Fixed Based Operations, or FBOs-together with newly developed locations-to create electrified ground infrastructure for the Lilium Jet in key markets across Europe initially, with further sites in the Middle East planned.

05:16 EDT Stryker announces first Gamma4 Hip Fracture Nailing System surgeries in Europe - Stryker announced that the first surgeries using the Gamma4 Hip Fracture Nailing System in Europe were completed at the Luzerner Kantonsspital LUKS, at the Centre Hospitalier Universitaire Vaudois, or CHUV, in Lausanne, Switzerland, and at Les Hopitaux Universitaires de Strasbourg in France. Stryker will debut the system during a live broadcast event in Germany, on June 4, highlighting key insights and case discussions.

05:12 EDT Allot Ltd.appoints Liat Nahum as CFO - Allot (ALLT) announced the appointment of Liat Nahum as the new CFO of the company. Nahum, who will join Allot on July 1, brings with her financial and international management experience from leadership roles at publicly listed technology companies. Prior to joining Allot, Nahum served for more than 20 years in a wide range of financial leadership roles, most recently as a strategic business executive and director of finance at Amdocs (DOX).